777 related articles for article (PubMed ID: 3292571)
21. Gonadotropin, estrogen and progesterone response to long term gonadotropin-releasing hormone infusion at various stages of the menstrual cycle.
Jewelewicz R; Dyrenfurth I; Ferin M; Bogumil J; Vande Wiele RL
J Clin Endocrinol Metab; 1977 Oct; 45(4):662-7. PubMed ID: 334788
[TBL] [Abstract][Full Text] [Related]
22. Pulsatile control of reproduction.
Lancet; 1984 Aug; 2(8399):382-3. PubMed ID: 6147459
[TBL] [Abstract][Full Text] [Related]
23. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.
Couzinet B; Young J; Kujas M; Meduri G; Brailly S; Thomas JL; Chanson P; Schaison G
J Clin Endocrinol Metab; 1999 Nov; 84(11):4191-6. PubMed ID: 10566671
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
25. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
[TBL] [Abstract][Full Text] [Related]
26. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
[TBL] [Abstract][Full Text] [Related]
27. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of the potential utility of LHRH agonists and antagonists for fertility control.
Vickery BH
J Steroid Biochem; 1985 Nov; 23(5B):779-91. PubMed ID: 3001420
[TBL] [Abstract][Full Text] [Related]
29. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
31. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
[TBL] [Abstract][Full Text] [Related]
32. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
33. Luteinizing hormone releasing hormone analogues for contraception.
Nillius SJ
Clin Obstet Gynaecol; 1984 Dec; 11(3):551-72. PubMed ID: 6391776
[TBL] [Abstract][Full Text] [Related]
34. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.
Bagatell CJ; Conn PM; Bremner WJ
Fertil Steril; 1993 Oct; 60(4):680-5. PubMed ID: 8405525
[TBL] [Abstract][Full Text] [Related]
35. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
36. Current status of antagonistic analogs of LH-RH as a contraceptive method in the female.
Schally AV
Res Front Fertil Regul; 1983 Jul; 2(5):1-16. PubMed ID: 12179624
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of ovulation by low-dose mifepristone (RU 486).
Ledger WL; Sweeting VM; Hillier H; Baird DT
Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
[TBL] [Abstract][Full Text] [Related]
39. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
40. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
